European procurement models that focus solely on the lowest-cost generics are jeopardizing efforts to strengthen the supply chain and secure investments in local manufacturing, says Christoph Stoller, president of Medicines for Europe.

A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.

A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.